There should be more “checks and balances” on incentives for companies developing orphan drugs and the criteria for determining EU orphan status, says the G-BA, Germany’s federal health insurance and reimbursement authority.
The high prices that companies often charge thanks to their orphan status mean that many rare disease patients in Europe...







